Manremyc opens a funding round of 250,000 euros through the Capital Cell platform
Manremyc, a spin-off of the IGTP specialised in the development of a probiotic against tuberculosis, has opened a funding round through Capital Cell, the first on-line investment platform in Europe specialized in biomedicine. The objective of the campaign is to reach 250,000 euros, with a minimum investment requirement per person of only 600 euros. Up to now, the company has secured 35% of the investment, which includes participation from the Reig family, main shareholders in the pharmaceutical company Reig Jofre.